Quality of life with second or third line nab-paclitaxel-based regimens in advanced non-small-cell lung cancer

Author(s):
Aix, S.P.; Talbot, D.; Govindan, R.; Dols, M.C.; Postmus, P.E.; Lewanski, C.; Bennouna, J.; Fischer, J.R.; Juan-Vidal, O.; Stewart, D.J.; Ardizzoni, A.; Bhore, R.; Wolfsteiner, M.; Reck, M.; Ong, T.J.; Morgensztern, D.
Published
2020
Publication type
Article / Letter to editor

Abstract

Aim: Evaluate quality of life (QoL) in patients with advanced non-small cell lung cancer treated with second or third line nab-paclitaxel +/- durvalumab. Patients & methods: Longitudinal QoL was assessed using Lung Cancer Symptom Scale, EuroQoL Five-Dimensions Five-Levels and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30-item core. Results: QoL was generally stable through eight treatment cycles (both arms). Clinically meaningful improvement from baseline was noted in Lung Cancer Symptom Scale (overall constitutional score and three-item index [nab-paclitaxel + durvalumab]) and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30-item core (global health status/QoL and emotional functioning [both arms] and pain [nab-paclitaxel + durvalumab]) analyses. EuroQoL Five-Dimensions Five-Levels domains were stable/improved or completely resolved at least once in 19-56% and 9-51% of patients, respectively. Conclusion: While QoL trends were promising, additional data are required to support these regimens in this setting.

durvalumabEORTC QLQ-C30EQ-5D-5Llung cancer symptom scalenab-paclitaxelnon-small cell lung cancerquality of life
Date issued
2020-04-01
Language
English
Publisher
FUTURE MEDICINE LTD
Is part of
Future Oncology (2020), Vol. 16, no. 12, p. 749-762
hdl
1887/3184835
doi
10.2217/fon-2019-0796
URL
https://www.futuremedicine.com/doi/10.2217/fon-2019-0796